We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current BGLC market cap is 8.33M. The company's latest EPS is USD -0.1488 and P/E is -3.16.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | ||
| Total Revenue | 2.38M | 2.88M | 2.75M | 2.25M | 2.58M |
| Operating Income | -168k | -155k | -2.53M | 257k | -79k |
| Net Income | -69k | -259k | -2.61M | 307k | -104k |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 12.28M | 13.43M | 11.11M | 10.26M |
| Operating Income | 1.27M | 1.06M | -291k | -2.59M |
| Net Income | 1.09M | 752k | -356k | -2.63M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | ||
| Total Assets | 8.19M | 7.9M | 11.47M | 11.4M | 11.16M |
| Total Liabilities | 1.63M | 1.94M | 1.78M | 1.74M | 1.82M |
| Total Equity | 6.56M | 5.96M | 9.69M | 9.66M | 9.34M |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 10.12M | 9.57M | 8.74M | 11.4M |
| Total Liabilities | 3.45M | 2.39M | 2.08M | 1.74M |
| Total Equity | 6.66M | 7.18M | 6.67M | 9.66M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | ||
| Operating | -119k | -140k | -1.04M | -1.3M | -34k |
| Investing | -5k | -8k | -368k | -383k | 24k |
| Financing | N/A | -4k | 5.74M | 5.76M | 24k |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 553k | 9k | 544k | -1.3M |
| Investing | 1.32M | -491k | -451k | -383k |
| Financing | -5k | -28k | 116k | 5.76M |
| Market Cap | 8.33M |
| Price to Earnings Ratio | -3.16 |
| Price to Sales Ratio | 0.81 |
| Price to Cash Ratio | 3.16 |
| Price to Book Ratio | 0.86 |
| Dividend Yield | - |
| Shares Outstanding | 17.67M |
| Average Volume (1 week) | 27.84k |
| Average Volume (1 Month) | 333.91k |
| 52 Week Change | -86.52% |
| 52 Week High | 9.49 |
| 52 Week Low | 0.31 |
| Spread (Intraday) | 0.03 (5.89%) |
| Company Name | BioNexus Gene Lab Corporation |
| Address |
1309 coffeen avenue ste 1200 sheridan, wyoming 82801 |
| Website | https://www.bionexusgenelab.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
